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บทคดัยอ่  
วตัถปุระสงค:์ เพื อศกึษาความชุกของการกดไวรสัและปจัจยัที มคีวามสมัพนัธ์กบั
การกดไวรสัของวยัรุ่นไทยที ตดิเชื อเอชไอว/ีเอดส์จากมารดาในเขตภาคอีสาน
ตอนล่าง วิธีการศึกษา: งานวจิยัแบบภาคตดัขวาง ใช้แบบสอบถามและแบบเก็บ
ข้อมูลทางคลนิิกเก็บขอ้มูลในกลุ่มวยัรุ่นตดิเชื อเอชไอว/ีเอดส์จากมารดาที มารบั
บรกิาร ณ คลนิิกภูมคิุม้กนั โรงพยาบาลในเขตจงัหวดัสุรนิทร์ บุรรีมัย ์และรอ้ยเอ็ด 
ระหวา่งเดอืน มกราคม ถงึ เมษายน 2557 วเิคราะหข์อ้มลูโดยใชส้ถติเิชงิพรรณนา
และวเิคราะห์การถดถอยโลจสิตกิส ์ ผลการศึกษา: วยัรุ่นไทยที ตดิเชื อเอชไอว/ี
เอดส์จากมารดาในเขตภาคอีสานตอนล่างจํานวน 245 คน จากโรงพยาบาลแห่ง
จากจงัหวดัสุรนิทร์ บุรรีมัย ์และรอ้ยเอด็ จาํนวน 11, 7 และ 3 แห่ง ตามลําดบัรวม 
21 แห่ง ส่วนใหญ่เป็นเพศหญิง (รอ้ยละ 57.55) อายุเฉลี ย 15 ปี(15.41 ± 2.41) 
กําลงัศึกษาอยู่ (ร้อยละ 76.73) ไม่มีผูดู้แลกํากบัในการรบัประทานยา (ร้อยละ 
62.45) มอีตัราการกดไวรสัเท่ากบัรอ้ยละ 85.31 ปจัจยัที มคีวามสมัพนัธ์กบัการกด
ไวรสัอย่างมนีัยสําคญัทางสถิตไิดแ้ก่  ความร่วมมอืในการรกัษาดว้ยยาต้านไวรสั
ตั  งแต่ร้อยละ 95 เป็นตน้ไป (OR = 12.73; 95%CI = 5.01 – 32.40) ระดบัเม็ด
เลอืดขาวชนิดซดีโีฟรม์ากกว่า 600 เซลล์ต่อมล. (OR = 11.10; 95%CI = 3.70 – 
33.25) และระดบัเมด็เลอืดขาวชนิดซดีโีฟร ์401 – 600 เซลล์ต่อมล. (OR = 6.20; 
95%CI = 1.92 – 20.00) สรปุ: วยัรุ่นไทยที ตดิเชื อเอชไอว/ีเอดสจ์ากมารดาในเขต
ภาคอสีานตอนล่างมอีตัราการกดไวรสัรอ้ยละ 85.31 ปจัจยัที มคีวามสมัพนัธ์กับ
การกดไวรสัอยา่งมนีัยสําคญัทางสถติไิดแ้ก่ ความร่วมมอืในการรกัษาดว้ยยาตา้น
ไวรสัและระดบัเมด็เลอืดขาวชนิดซดีโีฟร ์ 
คาํสาํคญั: การกดไวรสั, วยัรุน่, เอชไอว/ีเอดส,์ ความร่วมมอืในการรกัษา 
Abstract 
Objective: To explore prevalence of viral suppression and to identify 
factors associated with viral suppression among perinatally infected Thai 
adolescents living HIV/AIDS (ALWHs) in Lower North-Eastern Region, 
Thailand. Methods: A cross-sectional study. Questionnaires and clinical 
data collection form were employed to collect data from perinatally infected 
Thai ALWHs at immunology clinic of public hospitals in Surin, Buriram and 
Roiet province from January – April 2014. Data were analyzed with 
descriptive statistics and logistic regression analysis. Results: A total of 
245 perinatally Thai ALWHs from 21 hospital sites were included into study. 
There were 11, 7 and 3 sites from Surin, Buriram and Roiet province, 
respectively. The majority of them were female (57.55%), mean age was 
15-year-old (15.41  2.41), studying at school (76.73%), and not having a 
caregiver (62.45%). The prevalence of viral suppression was 85.31%. 
Factors significantly associated with viral suppression were adherence level 
≥ 95% (OR = 12.73; 95%CI = 5.01 – 32.40), CD4 level more than 600 
cell/ml. (OR = 11.10; 95%CI = 3.70 – 33.25) and CD4 level 401 - 600 
cell/ml. (OR = 6.20; 95%CI = 1.92 – 20.00). Conclusions: Viral 
suppression was found in 85.31% of perinatally infected Thai ALWHs in 
Lower North-Eastern Region, Thailand. Factors associated with viral 
suppression were adherence to ART and CD4 level.  
Keywords: viral suppression, adolescents, HIV/AIDS, adherence  
  
Introduction
Antiretroviral drugs (ARV) are pharmacologic agents that 
have led to dramatic improvements in health of persons 
living with HIV/AIDS. The treatment goal is to reduce HIV-
associated morbidity and prolong the duration and quality of 
survival.1 Several studies showed viral suppression with ARV 
has reduced HIV-related morbidity and mortality.2-5  
Viral suppression in an ART-naïve patient remains that a 
viral load < 50 RNA copies per ml or a load below the limit 
of detection of the most sensitive assay available with the 
first 12 – 24 weeks of therapy.6,7 Previous studies showed 
several predictors of viral suppression including high potency 
of ARV regimen, excellent adherence to treatment regimen8, 
low baseline viremia9, higher baseline CD4 cell count10 and 
rapid reduction of viremia in response to the treatment.8,11  
Older children and adolescents are the group at risk of 
treatment failure.12-14 Only 50% of adolescents were reported 
to have maintained an undetectable viral load at one year 
after achieving optimal control in a U.S. cohort.15 Recent 
data from a study in Europe showed that the rate of ART 
treatment failure in children was about two times higher than 
that in adults with heterosexually transmitted HIV.16 
Care for this group is more complex than that of infected 
adults. Especially during the transition from children to 
adolescence, the ability to accept themselves as an HIV-
infected person is troublesome because they have never had 
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a normal life without the disease, while all adults are infected 
through the experience of the foregoing.17,18  
In Thailand, although perinatally HIV-infected rate 
declined from 3.2% in 2010 to 2.4%, 2.3% and 1.8% in 
2011, 2012 and 2013, respectively19, but a cumulative 
number of children living with HIV/AIDS were raising from 
10,886 cases in 2008 to 14,751 cases in 2013.19 Most of 
them were in North-Eastern region (30.07%).19 However, we 
have limitation of data resource for the number of all ALWHs 
in Thailand because the cut point of age for children and 
adults in national program report was 15 years.19 Therefore, 
the quality of HIV care report in ALWHs could not be 
evaluated and compared with other areas. In this study we 
collected data from public hospitals in the lower North-
Eastern region of Thailand where the prevalence of HIV 
positive persons was high (5,418, 5,695 and 5,744 cases for 
Surin, Buriram and Roiet provinces) and the number of 
prenatally infected ALWHs was at 160, 123 and 115 for 
Surin, Buriram and Roiet provinces.  
In Thailand, 69% of patients living with HIV/AIDS had 
adequate adherence, but the older children aged 10 - 19 
years were significantly less adherent than younger children 
14. At Surin Hospital, its’ 2010 report showed that seven out 
of 110 HIV-infected children (6%) stopped taking 
antiretroviral drugs. All of them were later found to have 
drug-resistance HIV.20 Regarding treatment adherence, 
teenagers are different from adults. Programs which are 
successfully implemented in adults may be inapplicable to 
young people.  Regular practice of healthcare providers in 
Thai public hospitals starts from informing HIV-infected 
patients about their disease and treatment options. For the 
infected children, this is not always the case. Some children 
might have not been informed about the condition because 
they are not ready, both physically and mentally. They might 
not recognize their own illness. Each child is informed at 
different ages, mostly in the range of 9-10 years.21 Care for 
infected children is more complex than that of infected 
adults. Especially during the transition into adolescence, the 
ability to accept themselves as an HIV-infected person is 
troublesome. This is because they have never had a normal 
life without the disease, while all adults are infected through 
the experience of the foregoing.17,18 Their attitudes and 
beliefs on HIV/AIDS are very important to improve the 
HIV/AIDS-caring systems designed for adolescents and may 
place a burden of HIV infection in Thailand in the future.   
Several studies showed that psychosocial factors 
including depression, stigma and discrimination, family 
relationships and disclosure of HIV status with others played 
important roles in ART adherence.22-26 This corresponds to 
studies conducted in Thailand showing that access to health 
services, good relationships in the family, and disclosure of 
HIV status with others were factors contributing to better 
ART adherence.27 Most teens wanted their provider to ask 
them about their spiritual beliefs during some visits, 
especially when dealing with death/dying or chronic illness, 
but only 18% had ever shared these beliefs with their 
healthcare provider.28 Thus, to improve long-term adherence 
with ART, the healthcare team has to pay attention to both 
the patients’ medical and psychosocial factors.29 Among 
various psycosocial factors, those from the Health Belief 
Model and the Theory of Planned Behavior (TPB) are 
promising determining factors for adherence. The HBM was 
guided by Rosenstock, Strecher & Becker30 and the TPB 
was guided by Ajzen.31   
HBM perception variables were significantly associated 
with adherence to antiretroviral and use of alternative 
therapies. Perceived susceptibility to AIDS was positively 
associated with adherence to antiretroviral and use of 
alternative therapies. Additionally, patients who perceived 
higher barriers to using antiretroviral were significantly more 
likely to use alternative therapies. Among older HIV-infected 
patients, those who perceived themselves vulnerable to 
AIDS also demonstrated greater adherence to prescribed 
antiretroviral. A higher perception of susceptibility to AIDS 
was also associated with use of alternative therapies. These 
factors can be utilized in the development of specific 
strategies to maximize treatment adherence among older 
HIV patients, as well as patients in younger age groups.  
Data also show that reducing patient perceived barriers to 
the use of antiretroviral should increase treatment adherence 
and outcomes.32  
The utility of TPB in HIV continues to be identifying 
influential factors in HAART adherence by individual in-depth 
interviews. Previous studies show that participants identified 
seven outcomes of treatment adherence (e.g., feeling good 
and controlling the virus), six groups of influence to 
adherence (e.g., family, partner/spouse), and nine 
impediments to adherence (e.g., appointment scheduling, 
side effects of treatment). Results also showed perceiving 
costs of services and barriers to communication affected 
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both HAART adherence and HIV testing.33 Some studies 
used TPB to improve patients behavior in HIV testing34 and 
to enhance the success of programs for behavioral change 
in HIV35 These studies included an element of how attitudes 
may affect the perceptions of this disease and how these 
attitudes influence behavior and behavioral intent of 
HIV/AIDS.36   
Adherence with ART is an important factor to achieve the 
goal of ART treatment. Literature suggests that long-term 
ART with at least 95% adherence is concordant with a good 
clinical outcomes.37-39 It helps reducing HIV/AIDS related 
mortality and morbidity.40,41 In addition to adherence, whether 
any of psychosocial factors previously mentioned could 
directly associate with viral suppression is critical in 
identifying patients with potential to have viral suppression 
problem.  
Studies related to factors affecting viral suppression of 
Thai adolescents living with HIV/AIDS (ALWHs) remains very 
limited. This study aimed to explore viral suppression rate 
and to assess factors, including psychosocial ones, affecting 
viral suppression of Thai ALWHs in Lower North-Eastern 
Region, Thailand.   
   
Methods 
Study Design and Sample 
A questionnaire and clinical information collecting form 
were used in this cross-sectional study. The questionnaire 
explored ALWHs’ demographic characteristics and their 
knowledge, attitude and belief about disease and medicine. 
The sample size was calculated using Taro Yamane’s 
formula of which at least 200 cases were required. The 
study’s samples were ALWHs followed up at public hospitals 
in the Lower North-Eastern Region of Thailand (Surin, 
Buriram and Roiet provinces) during January – April 2014. 
Purposive sampling technique was used. We included only 
hospitals that had permission to collect data from the 
hospital directors.  
Inclusion criteria consisted of those ALWHs who (1) were 
perinatally infected with HIV-1, (2) had been taking 
antiretroviral therapy for at least one year, (3) were at the 
age between 10 - 18 years, (4) had already disclosed their 
infection status, (5) were able to read and write in Thai, and 
(6) were willing to participate in the study with their informed 
consent and the assent from their guardian such as parent, 
grandparent, or other relatives. Only those whose informed 
consents gained from themselves and their guardians were 
invited to participate to the study.  
We selected the age group of 10 – 18 years because 
most of immunology clinics in the Lower North-Eastern 
Region public hospitals serve HIV infected children from their 
early age to up to 18 years. HIV-infected persons older than 
18 years are transferred to adult immunology clinic.  
 
Procedure 
We developed a questionnaire about attitudes and 
beliefs in HIV/AIDS disease and medicine based on 
constructs of the Health Belief Model (HBM) and the Theory 
of Planned Behavior (TPB). These HBM constructs included 
perceived susceptibility (one's subjective perception of the 
risk of contracting a health condition), perceived severity 
(feelings concerning the seriousness of contracting an illness 
or of leaving it untreated, including evaluations of both 
medical and clinical consequences and possible social 
consequences), perceived barriers (potential negative 
consequences that may result from taking particular health 
actions, including physical, psychological, and financial 
demands), perceived benefits (believed effectiveness of 
strategies designed to reduce the threat of illness), self-
efficacy (belief in being able to successfully execute the 
behavior required to produce the desired outcomes), and 
cue to action (vents, either internal factors, e.g., physical 
symptoms of a health condition, or external factors, e.g., 
media publicity and healthcare team relationship, that 
motivate people to take action). The constructs from TPB 
included subjective norm (in a form of perceived stigma and 
discrimination) and perceived behavioral control.  
All questions of attitudes and beliefs included those 
measuring 8 domains, namely perceived susceptibility (3 
items), perceived severity (3 items), perceived benefit (1 
item), perceived susceptibility (3 items), perceived barriers 
(11 items), self-efficacy (4 items), cue to action (4 items), 
and stigma and discrimination (3 items). Examples of these 
questions are as follows: if not taking medicine on time, I will 
not stay healthy (perceived susceptibility), if I do not take 
medicine, I will get complication (perceived severity), 
medicine helps boost my immune so that I will not get sick 
often (perceived benefit), I have difficulty showing at the 
appointment (perceived barrier), I think that taking medicine 
on time is not difficult to do (self-efficacy), if there is 
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someone reminding me to take medicine, I will be more 
likely to take the medicine (cue to action), and I feel that I 
am isolated from the group (stigma and discrimination).   
All items were assessed by a 5-point Likert-type scale, 
ranging from 1-strong disagree to 5-strongly agree. Score of 
each domain was obtained by summing scores of all items in 
that domain divided by total number of items in the domain, 
resulting in a possible range of 1 – 5. The validity was 
assessed by three experts, specifically, two university faculty 
members with experience in health behavior research and a 
pediatrician with experience in caring ALWHs at the 
immunology clinic, Surin Hospital. These constructs based 
BHM and TPB possessed high reliability levels with 
Cronbach’s alpha coefficients ranging from 0.65 to 0.82, 
except for perceived benefit which had only 1 item.  
Questionnaire on knowledge consisted of 22 items with 
true/false answer covering 3 domains HIV/AIDS, namely 
transmission, progression, and treatment and medicine. 
Reliability of these knowledge questions was high with 
Kuder-Richardson-20 coefficient of 0.81.   
Patient’s medical record was used to collect clinical 
information, including age at the start of ARV, duration of 
ARV, CD4 level and adherence level. Average score of the 
last two visits were used to calculate the patient’s CD4 level. 
Adherence for each participant was calculated by using 
average percentage of pill count adherence in the last two 
visits and co1nfirmed with an interview record. If the 
interview data do not agree with the pill count data, the 
interview data were used. Adherence was a proportion of 
corrected doses taken by total doses. The most recent viral 
load was used for identifying the individual’s viral 
suppression status.  
The researcher or healthcare practitioners who worked at 
immunology clinics described the study protocol for the 
eligible ALWHs and their guardians while they were waiting 
to see their doctor. Those who agreed to participate were 
asked to sign the assent and consent forms and to fill in the 
questionnaire. Clinical data were collected later on and 
matched with questionnaire by an assigned code for 
concealing the individual identities.  
 
Data Analysis 
Individuals with a viral load less than < 50 copies/ml was 
identified as having viral suppression. Knowledge, attitudes 
and beliefs were grouped into “High” and “Low to moderate” 
groups based on a cut-off at 75th percentile. Descriptive 
statistics including frequency, percent and mean ± SD, were 
used. Logistic regression analysis was used to identify 
factors affecting viral suppression. A statistical significance 
level of 0.05 was set.  
  
Ethics approval 
This study received ethics approval from the Ethical 
Review Committee of the Faculty of Pharmacy, Chiang Mai 
University and the Ethical Committee of Surin Hospital. 
Permission from the director of community hospitals were 
gained from the hospitals with no ethical committee.  
    
Results  
There were a total of 245 participants (61.56%) from 398 
cases of target population (Table 1). Data were gathered 
from 21 sites, specifically, 11, 7 and 3 hospitals from Surin, 
Buriram and Roiet province, respectively. The majority of 
them were female (57.55%) with a mean age of 15 years old 
(15.41 ± 2.41). They were enrolled in school (76.73%), - 
 
Table 1 Demographic characteristics of study participants (n = 
245)  
Characteristics Number (%) 
Gender  
Male 104 (42.45) 
Female 141 (57.55) 
Age (year)  
10 - 15 123 (50.20) 
16 - 18 122 (49.80) 
Education status  
Enrolled  188 (76.73) 
Dropped out 57 (23.27) 
Transportation  
Convenient 176 (71.84) 
Distressful  57 (23.27) 
Very distressful 12 (4.89) 
Friend disclosure  
Yes 167 (68.16) 
No 78 (31.84) 
Community disclosure  
Yes 187 (76.33) 
No 58 (23.67) 
Having a caregiver*  
Yes 92 (37.55) 
No 153 (62.45) 
Family income (baht/month)  
Unknown 158 (64.49) 
Known 87 (35.51) 
Range 300 – 30,000 
≤ 1,000 25 (28.74) 
1,001 – 3,000 34 (39.08) 
3,001 – 6,000 14 (16.09) 
> 6,000  14 (16.09) 
 * A person who take care ALWH for medicine management  
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having convenient transportation to the hospital (71.84%) 
and not having a caregiver to help with their medicine 
management (62.45%). The average family income was 
4,161 baht/month (4,160.90 ± 5,119.49). Most of them were 
reported that they had disclosed their disease conditions to 
their friends (68.16%) and community (76.33%). The 
demographic characteristics of participants were shown in 
Table 1. 
For clinical characteristics, almost 80.41% of the 
respondents had the adherence level ≥ 95 %. The mean of 
adherence level was 94.64 ± 12.03. From the medical 
records, 50.61% had started their ARV at age 12 – 96 
months, and 47.35% had been on the ART for 49-96 
months.  
According to their ARV regimen treatment, most of them 
got the first line drugs (66.22%) which was a combination of 
two nucleoside reverse-transcriptase inhibitors (NRTIs) plus 
a non-nucleoside reverse-transcriptase inhibitor (NNRTI). 
The mean CD4 level was 656 cells/ml ( 293.45), where 
59.18% of respondents had CD4 level at more than 600 
cell/ml and 24.09% of them had CD4 level at 401 - 600 
cell/ml. Viral suppressed was found in 209 cases from a total 
of 245 cases (85.31%). The clinical characteristics of study 
participants are shown in Table 2. 
 
 
Table 2 Clinical characteristics of study participants (n = 245)  
Characteristics Number (%) 
Adherence level (%)  
< 95 48 (19.59) 
 95 197 (80.41) 
Age at started ARVs (months)  
12 - 96 124 (50.61) 
97 - 114 100 (40.82) 
145 - 192 21 (8.57) 
Duration of ARVs (months)  
12 - 48 41 (16.73) 
49 - 96 116 (47.35) 
145 - 192 88 (35.92) 
ARV Regimen  
First line* 162 (66.22) 
Second line** 83 (33.88) 
CD4 level (cell/ml.)  
≤ 400 41 (16.73) 
401 - 600 59 (24.09) 
> 600 145 (59.18) 
Viral suppressed  
Yes 209 (85.31) 
No 36 (14.69) 
* First line drugs is a combination of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-
nucleoside reverse-transcriptase inhibitor (NNRTI). 
** Second line drugs is a combination of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus protease 
inhibitors (PIs). 
 
Knowledge, attitudes and beliefs regarding disease and 
medicines were classified into 2 groups using the 75th 
percentile because they were not normally distributed. 
Majority of them had high level of perceived severity 
(72.24%) and perceived benefit (70.20%), low to moderate 
level of knowledge (73.47%),  perceived susceptibility and 
barriers (59.18% and 72.27%, respectively).  Furthermore, 
they also had low to moderate level of self-efficacy (73.06%), 
cue to action (69.80%) and perceived stigma and 
discrimination (69.39%). Knowledge, attitudes and beliefs of 
study participants were shown in Table 3. 
 
Table 3 Knowledge, attitudes and beliefs of study participants 
(n = 245)  
Items 
Number of participants (%) by score level 
High level Low to moderate level 
Knowledge  65 (26.53) 180 (73.47) 
Perceived susceptibility  100 (40.82) 145 (59.18) 
Perceived severity  177 (72.24) 68 (27.76) 
Perceived barrier  68 (27.76) 177 (72.27) 
Perceived benefit  172 (70.20) 73 (29.80) 
Self–efficacy  66 (26.94) 179 (73.06) 
Cue to action  74 (30.20) 171 (69.80) 
Perceived stigma and discrimination  75 (30.61) 170 (69.39) 
   
 
Findings from univariate regression analysis revealed 
that education status, having caregiver, cue to action, CD4 
level and adherence level were statistically significant 
associated with viral suppression (Table 4). There were 
noted that ALWHs with studying status (OR = 2.84; 95%CI = 
1.35 – 5.98), having caregiver (OR = 3.59; 95%CI = 1.72 – 
7.51), CD4 level 401 – 600 cell/ml. (OR = 7.80; 95%CI = 
2.87 – 21.18), CD4 level more than 600 cell/ml (OR = 17.98; 
95%CI = 7.03 – 46.02), adherence level ≥ 95% (OR = 20.35; 
95%CI = 8.78 – 47.15) were more likely to have viral 
suppression.  
Finally, the results from multivariate regression analysis 
showed that adherence level and CD4 level were 
independently associated with viral suppression. Patients 
with adherence level ≥ 95% were more likely to have viral 
suppression (OR = 12.73; 95%CI = 5.01 – 32.40) after 
controlling for the effects of study status, having care giver 
and CD4 level. Moreover, patients with CD4 level more than 
600 cell/ml. and 401 - 600 cell/ml., compared to those with 
CD4 level 400 cell/ml or less, were more likely have viral 
suppression (OR = 11.10; 95%CI = 3.70 – 33.25; and OR = 
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6.20; 95%CI = 1.92 – 20.00, respectively), after controlling 
for the effects other factors. (Table 4)  
 
Table 4 Univariate and multivariate regression analysis of 
characteristics and viral suppression of study participants (n = 
245)   
Characteristics 
Crude OR  
(95%CI) 
Adjusted OR**  
(95% CI) 
Demographic characteristics   
Female (ref. = male) 1.86 (0.91 – 3.80) - 
Age 16 – 18 years (ref. = 10 - 15) 0.67 (0.33 – 1.367) - 
Enrolling in school (ref.=dropped out) 2.84 (1.35 – 5.98)* 1.65 (0.59 – 4.57) 
Convenient transportation (ref. = very distressful) 1.21 (0.25 – 5.84) - 
Distress transportation (ref. = very distressful) 1.07 (0.20 – 5.71) - 
Friend disclosed (ref. = no) 0.68 (0.30 – 1.52) - 
Community disclosed (ref. = no) 0.75 (0.31 – 1.81) - 
Having a caregiver (ref. = no) 3.59 (1.72 – 7.51)* 2.20 (0.84 – 5.76) 
Knowledge, attitudes and beliefs (ref. = low to moderate) 
High knowledge level  0.51 (0.24 – 1.06) - 
High perceived susceptibility level  0.84 (0.41 – 1.71) - 
High perceived severity level  0.71 (0.31 – 1.65) - 
High perceived barrier level  0.85 (0.39 – 1.84) - 
High perceived benefit level  1.04 (0.48 – 2.25) - 
High self-efficacy level  0.95 (0.43 – 2.10) - 
High cue to action level 0.84 (0.40 – 1.79) - 
High perceived stigma and discrimination level 1.00 (0.47 – 2.16)   - 
Clinical characteristics   
≥ 95% adherence (ref. = < 95%) 20.35 (8.78 – 47.15)* 12.73 (5.01 – 32.40)* 
Age at started ARV 97 – 114 months (ref. = 12 – 96) 0.83 (0.40 – 1.75) - 
Age at started ARV 97 – 114 months (ref. = 145 – 192) 0.95 (0.25 – 3.59) - 
Duration of ARV 49 - 96 months (ref. = 12 – 48) 0.49 (0.14 – 1.79) - 
Duration of ARV more than 96 months (ref. = 12 – 48) 0.33 (0.09 – 1.20) - 
CD4 level 401 – 600 cell/ml. (ref. = ≤ 400) 7.80 (2.87 – 21.18)* 6.20 (1.92 – 20.00)* 
CD4 level more than 600 cell/ml. (ref. = ≤ 400) 17.98 (7.03 – 46.02)* 11.10 (3.70 – 33.25)* 
  * Statistically significant (P-value < 0.05)  
 
 
 
Discussions and Conclusions  
 
This study found that Thai ALWHs in Lower North-
Eastern Region have high level of viral suppression 
(85.31%). The rate was higher than HIV-infected youth in the 
United States (37%).42 This might suggest that the practice 
guideline of national policy on HIV/AIDs of caring HIV/AIDs 
infected person is very effective for health care team. These 
were supported by the National Access to Antiretroviral 
Program for people living with HIV/AIDS (NAPHA) in 
Thailand which implemented with all major program 
components; ARV protocol development, healthcare 
professional training, drug supply chain management, 
laboratory network formation, monitoring and evaluation and 
multi-sector and PHA involvement since 2001.43 
Our study finding highlight that adherence level  ≥ 95 % 
was strongest associated with viral suppressed as in the 
relevant predictor from several studies22-26 and guidelines.6,44 
Previous studies noted viral suppressed required at least 
95% adherence.6,45,46 Additional finding, data indicated that 
patients with CD4 level of 401 - 600 cell/ml. was also the 
predictor of viral suppressed compared with those with CD4 
level ≤ 400 cell/ml. and those with CD4 more than 600 
cell/ml gained the most benefit from the treatment. The 
guidelines of HIV treatment recommended that CD4 is the 
indicator of immune function in HIV-infected patients6,44 and 
also predictor of viral suppressed, disease progression and 
survival according to findings from clinical trials and cohort 
studies.47,48  
The findings found that viral suppression was not 
associated with knowledge, attitudes, beliefs, and others 
demographics. Therefore, to gain favorable viral suppressed 
in ALWHs, healthcare providers should focus on improving 
patient’s adherence and using CD4 as an outcome indicator. 
It could also be attributable to the fact that these 
psychosocial factors assert their effects trough adherence.  
 
Strengths and limitations  
This study had a large number of participants from the 
pool of the target population (61.56%). Although we included 
several psychosocial characteristics from the theories, those 
factors had shown no significant effect on ALWH’s viral 
suppression. The questions might not be adequately 
sensitive to detect the nature of these factors. Additionally, 
since it was a self-administered questionnaire, it could be a 
bias where the respondents did not tell the truth. In addition, 
information bias might exist as several other demographics 
were not included. Finally, with a quasi-experimental design, 
there was a limitation due to a lack of true control group to 
ensure the study results from the intervention program.  
 
Conclusion  
Among perinatally infected Thai ALWHs in Lower North-
Eastern Region, there was 85.31% viral suppression. 
Factors associated with viral suppression were adherence 
level of ≥ 95% and a CD4 level higher than 400 cells/ml.  
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